CA - Acasti Pharma GAAP EPS of -$0.10
- Acasti Pharma press release ( NASDAQ: ACST ): Q1 GAAP EPS of -$0.10.
- Cash, cash equivalents and short-term investments of $38.4M.
- Given certain cost savings and overall efficiencies implemented across the organization, management believes that it now has sufficient capital to fund operations through at least March 2024, allowing for the advancement of GTX-104 through Phase 3 and advancing GTX-102 and GTX-101 to key value inflection points.
- The company remains on track to initiate the PK bridging study of GTX-102 in the third calendar quarter of 2022 and is expected to report out topline results on schedule before the end of calendar 2022. Assuming the PK bridging study meets its primary endpoint, and based on the FDA’s subsequent guidance, the Company plans to conduct a Phase 3 safety and efficacy trial in Ataxia Telangiectasia (A-T) patients. The Phase 3 study is expected to be initiated in the second half of calendar 2023.
For further details see:
Acasti Pharma GAAP EPS of -$0.10